Merck and Modena announced that the Phase III clinical trial of Intismeran has reached a major end. Trials have shown that the vaccine prevents melanoma from recurring.

Merck and Modena announced that the Phase III clinical trial of Intismeran has reached a major end. Trials have shown that the vaccine prevents melanoma from recurring.